β-glucuronidase and β-glucosidase activity in stool of children with Inflammatory Bowel Disease.
Marta Mroczyńska , Mirosława Gałęcka, Patrycja Szachta, Dorota Kamoda , Zdzisława Libudzisz , Dorota Roszak Pol J Microbiol 2013; 62 (3): ICID: 1072800 Article type: Short communication IC™ Value: 6.00
Abstract provided by Publisher
Purpose: Aim of the study was to analyze the differences in the activity of selected faecal enzymes (β-glucuronidase, β-glucosidase) in the stool of children with inflammatory bowel disease (IBD), in comparison with healthy subjects. We also assessed relationship between the clinical manifestation of the disease, the level of disease activity and the level of the faecal enzymes.
Material and methods: 68 children with IBD and 38 healthy individuals were involved to the study. The disease activity for Crohn Disease (CD) was determined according to the PCDAI scale (Pediatric Crohn Disease Activity Index) and for ulcerative colitis (CU) according to the Truelove-Witts scale. Activity of β-glucuronidase and β-glucosidase was determined by spectrophotometry.
Results: The activity level of β-glucuronidase in stool increases with age in healthy controls, but not in IBD group. The activity of β-glucuronidase in children with IBD was two times lower than in healthy group and did not depend on the clinical manifestations of disease (CD, CU, CI). In contrast, β - glucosidase activity in IBD and healthy subjects stools did not differ significantly. The activity of β -glucosidase increased with age in IBD children, but not in group of healthy ones. Activity of β-glucuronidase and β-glucosidase in stool was not significantly different in CU, CD and CI β-glucuronidase and β-glucosidase activity did not depend on the treatment implementation.
Conclusions: β-glucuronidase activity in children’s with IBD stool was significantly lower than in healthy individuals. Explanation of the reason for this differences may be valuable in determining the pathogenesis and effective therapy in IBD. Determination of β-glucuronidase activity in stool can be useful tool in the assessment of IBD development risk.